M-chai.Bk
M-CHAI.BK operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medications and related healthcare solutions.
Business. M-CHAI.BK operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medications and related healthcare solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
M-CHAI.BK operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medications and related healthcare solutions.
M-CHAI.BK has a liquidity position that is relatively constrained, as evidenced by a current ratio of 0.5, indicating that the company's current liabilities significantly exceed its current assets. The company's price-to-book ratio of 1.34 suggests that the market values the company at a premium to its book value, but the price-to-tangible-book ratio is the same, indicating that intangible assets do not significantly affect the valuation.
Profitability metrics for M-CHAI.BK show a return on equity of 6.84%, which is a measure of how effectively the company uses shareholders' equity to generate profit. However, the return on assets of 1.38% is relatively low, suggesting that the company is not efficiently using its assets to generate earnings. These figures should be compared to the industry median to determine if the company is outperforming or underperforming its peers.
The company's revenue is primarily concentrated in the pharmaceutical segment, with no disclosed geographic diversification. This concentration may pose a risk if the market for pharmaceutical products experiences a downturn. The company's exposure to a single segment means that its performance is highly dependent on the success of this area.
Looking at the growth trajectory, M-CHAI.BK has reported a net income of 152,791,130 THB, but the company's capital expenditure of -203,775,970 THB indicates a reduction in investment in long-term assets. The company's revenue of 6,526,481,240 THB and operating income of 460,652,950 THB suggest a stable but not rapidly growing business. The outlook for the next fiscal year is not explicitly provided, but the company's financial performance will be closely watched for signs of improvement or decline.
Risk factors for M-CHAI.BK include a high debt-to-equity ratio of 2.93, which indicates that the company is heavily leveraged. The liquidity risk is rated as medium, and the company has a low dilution risk. The risk assessment also notes that net cash is negative after subtracting total debt, which could limit the company's ability to invest in growth opportunities or withstand financial downturns.
Recent events and filings for M-CHAI.BK include the latest actual EPS of 0.35 THB and actual revenue of 1,170,302,000 THB, as reported by analysts. These figures provide insight into the company's recent performance and may influence investor sentiment and stock price movements.
- M-CHAI.BK has a liquidity position that is relatively constrained, with a current ratio of 0.5.
- The company's return on equity is 6.84%, but the return on assets is relatively low at 1.38%.
- Revenue is primarily concentrated in the pharmaceutical segment, with no disclosed geographic diversification.
- The company has a high debt-to-equity ratio of 2.93, indicating significant leverage.
- Recent financial performance includes a net income of 152,791,130 THB and a capital expenditure of -203,775,970 THB.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- M-CHAI.BK Market data — financials · 2026-05-28
- Mahachai Hospital PCL Market data — analyst estimates · 2026-05-28